Perceptronix Medical Inc. Laboratories

Perceptronix Medical Inc. Laboratories

March 31, 2009 14:53 ET

Perceptronix Medical Inc: OralAdvance™ Offers April Discount for Oral Health Month

VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 31, 2009) - In support of National Oral Health Month (http://www.cda-adc.ca/en/cda/news_events/health_month/index.asp) in Canada, Perceptronix Medical Inc. is offering a 30% discount on OralAdvance™ (http://www.oraladvance.com/) tests ordered in the month of April.

OralAdvance™ is used by dentists to assess the cancerous potential of suspicious lesions in the oral cavity viewed by naked eye or oral visualization device (e.g. VELscope™ (http://www.velscope.com/)). Cells are collected from areas that look like they may be pre-cancer using OralAdvance™'s easy-to-use brush. These cells are then assessed at Perceptronix' Vancouver laboratory to determine whether they have abnormal DNA content as a result of large-scale changes indicative of cancer or pre-cancer. If early oral cancer is indicated, treatment is straight-forward and patient outcomes are favourable - when found early, the 5-year survival rate is 80-90%.

"Perceptronix (the maker of OralAdvance™) is very proud to support oral cancer awareness in this National Oral Health Month. Our hope for this promotion is to help people in Canadian communities by raising awareness of oral cancer and the need for regular oral cancer screening. In the Western world, more people die each year from oral cancer than from cervical cancer mainly due to late detection. These deaths are needless given how easy it is to visualize the oral cavity and assess lesions suspicious for cancer. We would like to see systematic early oral cancer detection programs implemented in Canadian dental offices. In support of this aim, we are offering OralAdvance™ tests to Canadian dentists at a significant discount for the month of April," explains Dr. Bojana Turic, Perceptronix President and CEO.

About OralAdvance™

With recent advances in visualization techniques for the oral cavity, dentists are encountering more suspicious lesions. OralAdvance™, with its soft cyto-brush sample collection kit, provides dentists with an informative new option for assessing these lesions before the invasive step of diagnostic biopsy. It provides an objective measure of gross DNA abnormality that can give additional information about the pre-malignant or malignant nature of a lesion.

About Perceptronix Medical Inc.

Perceptronix Medical Inc. (Vancouver, Canada) is a cancer diagnostics laboratory specializing in provision of innovative tests for the early detection of cancer based on quantitative cytology, including tests for oral cancer (www.OralAdvance.com) and lung cancer (www.LungSign.com). The Company's technology was developed in partnership with the British Columbia Cancer Agency (Vancouver, Canada). Quantitative cytology provides physicians with a cytopathology assessment based on an objective, computer-based measurement of large-scale DNA abnormality that can indicate precancerous or cancerous changes.

Contact Information